Protelight Pharma

Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., doing business as ProteLight Pharma, is a China-based, high-tech biopharmaceutical company established in 2009. The company focuses on the research, development, and production of peptide and small-molecule innovative drugs, specifically targeting infectious diseases, oncology, autoimmune disorders, and metabolic diseases such as obesity. They utilize advanced de novo design platforms, particularly for α-helical antimicrobial peptides (AMPs), to develop a diversified drug pipeline and improve industrialization processes through their proprietary membrane discrimination mechanism.

Beyond proprietary drug development, ProteLight Pharma provides pharmaceutical contract development and manufacturing organization (CDMO) services, offering peptide pharmaceutical research, synthesis, and customized production for clinical and commercial stages. The company maintains a strong intellectual property portfolio including numerous international patents and has participated in national scientific research projects. By integrating independent innovation with scalable production capabilities, ProteLight Pharma aims to address global public health challenges and antimicrobial resistance, advancing its lead candidates toward commercialization and later-stage clinical trials.